BRIEF-Amneal Pharmaceuticals Q4 Revenue USD 814.319 Million Vs. IBES Estimate USD 807.9 Million
AMRX has more than doubled off its 52-week low of $6.685.
Summary
Amneal Pharmaceuticals reported Q4 revenue of $814.319 million, exceeding the IBES estimate of $807.9 million. The company also issued its full-year guidance, forecasting revenue between $3,050 million and $3,150 million, adjusted EBITDA of $720 million to $760 million, and operating cash flow of $325 million to $375 million. This revenue beat signals a stronger-than-anticipated quarterly performance. The comprehensive full-year outlook provides crucial forward-looking data that will significantly impact analyst models and investor sentiment regarding the company's future financial trajectory.
At the time of this announcement, AMRX was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $6.69 to $15.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.